Select status:
Sort by:
Filter by expected publication date

Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and September 2026

Filter by area of interest
Filter by type
Showing 1 to 10 of 635
Title Type Expected publication date
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] Technology appraisal guidance Expected publication date:TBC 0
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839] Technology appraisal guidance Expected publication date:09 March 2022 20220309
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840] Technology appraisal guidance Expected publication date:21 September 2022 20220921
Medtech innovation briefings
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857] Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347 Technology appraisal guidance Expected publication date:TBC 0
Abicipar pegol for treating wet age-related macular degeneration ID1533 Technology appraisal guidance Expected publication date:TBC 0
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768] Technology appraisal guidance Expected publication date:TBC 0
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025] Technology appraisal guidance Expected publication date:TBC 0